BioCube, Inc.
BICB · OTC
1/31/2023 | 1/31/2022 | 1/31/2021 | 1/31/2013 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | -0.00 |
| FCF Yield | -3.76% | 0.00% | 0.00% | -25.47% |
| EV / EBITDA | 3.43 | 0.00 | 0.00 | -12.11 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | 0.00% | 108.51% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.62 | 0.08 | 0.13 | 0.07 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | -430.60% |
| Safety | ||||
| Net Debt / EBITDA | 0.01 | 0.00 | 0.00 | -9.43 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -1.06 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |